Navigation Links
NutraCea Announces First Quarter 2008 Financial Results

PHOENIX, May 12 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB), nutrient research and technology, today announced financial results for its first quarter ended March 31, 2008. Consolidated net revenues rose 155% to $5.1 million for the first quarter of 2008, compared to consolidated net revenues of $2.0 million for the first quarter of 2007. The $3.1 million increase was primarily due to a $860,000 increase in sales of products produced in the United States, an increase of $17,000 in royalty revenues and $2.2 million in sales from the Company's Irgovel subsidiary in Brazil for the period February 19, 2008 through March 31, 2008.

The Company reported a net loss of $(6.8) million, or $(0.05) per share, compared to a net loss of $(247,000), or $0.00 per share for first quarter 2007. The loss was primarily due to a $4.5 million increase in operating expenses and a net decrease in Other Income and Expenses (net) of $1.4 million.

Sales, General and Administrative (SG&A) expenses were $5.2 million, compared to SG&A of $2.3 million for the first quarter of 2007. This increase was primarily due to expanded investment in personnel, infrastructure and sales and marketing activities to meet anticipated future demands. In the quarter we wrote down $390,000 in connection with a doubtful note receivable. The Company's professional fees were $2.0 million compared to $459,000 for the same quarter last year. These expenses were primarily due to consulting and legal fees of approximately $621,000 in connection with marketing and business development, SOX 404 activities, the acquisition of Irgovel and our investment in PT Panganmas Inti Nusantara, an Indonesian Company (PIN), made through our Medan LLC subsidiary. We also incurred a $750,000 broker fee which included the estimated value of an option to be issued related to our investment PIN. Of the $5.2 million in SG&A during the quarter, approximately $1.5 million were non-cash charges.

Brad Edson, president and CEO of NutraCea, commented, "The revenues that we reported for our first quarter were significantly higher year-over-year and slightly lower than we anticipated over Q4 of 2007 as we purposely began to build inventory for product roll outs for new and existing customers that are expected to occur late in our third quarter and build into our fourth quarter. Currently, on a cost basis, we have approximately $2.8 million in domestic inventory, which is a large number for us but necessary in order for the Company to have sufficient quantities of supply to be able to meet anticipated sales demands later this year. We will continue to build our inventory from current levels and are in fact adding further temporary warehousing space to accommodate our inventory needs. When our expected new sales come in during the second half of the year, our inventory will decrease significantly.

"Our production capability will meaningfully increase this quarter and even though we will be adding to inventory during the quarter, we should see our revenue grow from our reported $5.2 million in sales in the first quarter to between $9.0 and $10.0 million in our second quarter."

Mr. Edson added, "We expect to see continued top line growth quarter over quarter for the balance of the year as additional production comes on line, and we later begin to pull down on our inventory. This should be accompanied by continued decreases in operating costs over the next few quarters. Furthermore, the Company anticipates it will be able to contractually secure additional international supply and production agreements for raw bran this calendar year that should increase our ability to satisfy the new and anticipated demand for NutraCea's products for future years."

About NutraCea

NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. Through its wholly owned subsidiary RiceX, the company manufactures and distributes products and food ingredients made from rice bran through its proprietary technology and processes. The company has developed intellectual properties to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health-promoting "nutraceuticals," including natural arthritis relief and cholesterol-lowering products. More information can be found in the company's filings with the SEC, and at the company's Web site

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding expected product demand, revenue, inventory levels, production capacity, operating costs and the ability to secure international supply and production agreements, all of which statements are subject to market and other risks. These statements are made based upon current expectations and actual results may differ from those projected, due to a number of risks and uncertainties. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the Company's most recent periodic report.

Investor Relations Contact:

Marilynn Meek

Financial Relations Board




March 31, December 31,

2008 2007



Current assets:

Cash and cash equivalents $5,816,000 $41,298,000

Restricted cash 5,281,000 758,000

Trade accounts receivable,

net of allowance for doubtful

accounts of $3,168,000 and

$2,999,000, respectively 3,066,000 2,346,000

Inventories 3,831,000 1,808,000

Notes receivable, current portion,

net of allowance for doubtful notes

receivable of $543,000 and $250,000,

respectively 7,145,000 2,936,000

Deposits and other current assets 2,480,000 2,545,000

Total current assets 27,619,000 51,691,000

Restricted cash 1,791,000 1,791,000

Notes receivable, net of current portion 44,000 5,039,000

Property and equipment, net 38,939,000 19,328,000

Investment in joint venture 9,348,000 1,191,000

Patents and trademarks, net of

accumulated amortization 5,534,000 5,743,000

Other non-current 50,000 -

Goodwill 52,765,000 39,510,000

Total assets $136,090,000 $124,293,000


Current liabilities:

Accounts payable and accrued liabilities $13,646,000 $7,506,000

Deferred revenue 291,000 90,000

Note payable, current portion 4,424,000 23,00

Total current liabilities 18,361,000 7,619,000

Long-term liabilities:

Long-term liabilities 6,278,000 -

Notes payable, net of current portion 71,000 77,000

Total liabilities 24,710,000 7,696,000

Commitments and contingencies

Shareholders' equity:

Common stock, no par value,

350,000,000 shares authorized,

145,525,000 and 144,108,000 shares

issued and outstanding 179,237,000 177,813,000

Accumulated deficit (67,968,000) (61,216,000)

Foreign currency cumulative

translation gain 111,000 -

Total shareholders' equity 111,380,000 116,597,000

Total liabilities and shareholders'

equity $136,090,000 $124,293,000




Quarters ended

March 31, 2008 March 31, 2007


Net product sales $5,084,000 $1,987,000

Royalty 27,000 10,000

Total revenue 5,111,000 1,997,000

Cost of goods sold 4,279,000 1,113,000

Product warranty cost 515,000 -

Total cost of sales 4,794,000 1,113,000

Gross Margin 317,000 884,000

Operating expenses

Research and development expenses 264,000 121,000

Selling, general and administrative expenses 5,178,000 2,293,000

Professional fees 1,958,000 459,000

Total operating expenses 7,400,000 2,873,000

Loss from operations (7,083,000) (1,989,000)

Other income (expense)

Interest and other income 260,000 512,000

Interest expense (120,000) -

Other income 245,000 -

Equity (loss) in joint venture (17,000) -

Gain on settlement - 1,250,000

Net loss before taxes (6,715,000) (227,000)

Provision for income taxes (37,000) (20,000)

Net loss $(6,752,000) $(247,000)

Basic and diluted earnings per share:

Basic loss per share $(0.05) $(0.00)

Weighted average basic number of shares

outstanding 144,779,000 111,959,000

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Announces Conference Call to Report Second Quarter Financial Results
4. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
5. NutraCea Provides Update on Domestic Operations
6. NutraCea Files Universal Shelf Registration Statement
7. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
8. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
9. NutraCea Appoints New Chief Financial Officer
10. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
11. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: